Hepatitis B Foundation responds to ACIP discussion on the hepatitis B birth dose vaccine. Read more here.

Hepatitis B Foundation responds to ACIP discussion on Dec. 4, 2025

We at the Hepatitis B Foundation are deeply disappointed and extremely concerned about today’s discussion during the Advisory Committee on Immunization Practices (ACIP) meeting. Overall, the meeting lacked transparency, with many of the presentations showing one-sided data, and several points made by Committee members clearly showed that they have a very specific agenda.

The hepatitis B vaccine birth dose has proven to be among our most effective tools for protecting infants from a preventable, cancer-causing disease. The committee members dismissed the extensive body of scientific data and real-life experience that prove the necessity, safety and value of the universal birth dose vaccine for hepatitis B.

The Hepatitis B Foundation will be paying close attention to tomorrow’s vote, and we will discuss the complex potential outcomes before issuing a further statement. As we work to determine the best ways to mitigate the likely damage caused by the future vote, our top priority remains the health and well-being of the up to 2.4 million people living with hepatitis B in the U.S., and the nearly 300 million people with the disease worldwide. We must protect future generations from hepatitis B, hepatitis D and liver cancer.

The Hepatitis B Foundation remains a source of fact-based information and will continue to work ensuring that every baby, child and adult has access to this lifesaving vaccine.